ClinicalTrials.gg

Multiple Myeloma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,763 studies for Multiple Myeloma across more than 10 countries. 770 are recruiting or about to start. 2,827 of them are mainly about Multiple Myeloma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Leukemia, Plasma Cell too: 3,776 studies, 776 open.

ClinicalTrials.gov finds 4,064 studies for Multiple Myeloma. How that becomes 3,763 here

This page counts the studies the registry files under Multiple Myeloma, and those it files under no condition that list Multiple Myelomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,064Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −12Filed under a narrower condition, counted on its own pageLeukemia, Plasma Cell 11
  3. −59List Multiple Myeloma as a condition, but the registry did not file them under itMost often written as “Smoldering Multiple Myeloma” (30), “Smoldering Plasma Cell Myeloma” (10), and “Multiple Myeloma in Relapse” (3). The registry filed 2 of them under no condition at all, and the others under other conditions only, most often Smoldering Multiple Myeloma (44) and Monoclonal Gammopathy of Undetermined Significance (11).
  4. −230Match it another way82 name it in the title, 2 in a keyword, and 146 by a synonym or other text the search reads.
  5. 3,763The count on this page88 of them list Multiple Myeloma in their own words; the registry filed them under no condition.

Status

Completed
1,705
Recruiting
585
Terminated
496
Active, not recruiting
330
Status unknown
279
Not yet recruiting
171

Phase

Phase 2
1,620
Phase 1
1,221
Phase 3
398
Early Phase 1
89
Phase 4
57

Where

United States
2,168
China
448
France
377
Spain
315
Germany
298
Italy
287

Who develops what

Add Multiple Myeloma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 82 programs from 51 companies, 69 with this as their studies’ main aim; 28 with a live phase 3 study; 18 primary completions in the next 12 months. Compare Beijing Biotech, GlaxoSmithKline and AbbVie here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
DexamethasoneRecent, repeated
Evidence
  • NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Dexamethasone” · registered Nov 2026
  • NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
  • NCT07903272 · Johnson & Johnson · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Dexamethasone” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Dexamethasone” · registered Oct 2026
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)2352 studies
pomalidomideRecent, repeated
Evidence
  • NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Pomalidomide Capsules” · registered Nov 2026
  • NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Pomalidomide” · registered Oct 2026
  • NCT07825064 · Hoffmann-La Roche · Phase 2 · live · background · “Pomalidomide” · registered Sep 2026
  • NCT07742215 · Biocad · Phase 3 · live · comparator · “Daratumumab + pomalidomide + dexamethasone” · registered Jul 2026
  • NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Pomalidomide Capsules” · registered May 2026
Bristol-Myers Squibb49% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 5 generics authorized1827 studies
daratumumabRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Daratumumab Injection (Subcutaneous Injection)” · registered Nov 2026
  • NCT07910903 · Keymed Biosciences Co.Ltd · Phase 3 · live · comparator · “Daratumumab” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Daratumumab” · registered Oct 2026
  • NCT07764861 · Innovent Biologics, Inc. · Phase 2 · live · background · “Daratumumab” · registered Aug 2026
  • NCT07742215 · Biocad · Phase 3 · live · comparator · “Daratumumab + pomalidomide + dexamethasone” · registered Jul 2026
Johnson & Johnson64% of its industry studies1629 studies
LenalidomideRecent, repeated
Evidence
  • NCT07903272 · Johnson & Johnson · Phase 3 · live · comparator · “Lenalidomide” · registered Oct 2026
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Lenalidomide” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Lenalidomide” · registered Oct 2026
  • NCT07764861 · Innovent Biologics, Inc. · Phase 2 · live · comparator · “Lenalidomide” · registered Aug 2026
  • NCT07735637 · AstraZeneca · Phase 3 · live · background · “Lenalidomide” · registered Jul 2026
Bristol-Myers Squibb61% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 4 generics authorized1218 studies
BortezomibRecent, repeated
Evidence
  • NCT07933432 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Bortezomib for Injection” · registered Nov 2026
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Bortezomib” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Bortezomib” · registered Oct 2026
  • NCT07764978 · AstraZeneca · Phase 3 · live · background · “Bortezomib” · registered Jul 2026
  • NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Bortezomib for Injection” · registered May 2026
Johnson & Johnson33% of its industry studiesUS: off-patent, 15 generics marketedEU: off-patent, 3 generics authorized1019 studies
carfilzomibRecent, repeated
Evidence
  • NCT07728188 · AbbVie · Phase 3 · live · comparator · “Carfilzomib” · registered Jul 2026
  • NCT07555938 · Hoffmann-La Roche · Phase 3 · live · comparator · “Carfilzomib” · registered Apr 2026
  • NCT07391657 · AstraZeneca · Phase 3 · live · comparator · “Carfilzomib” · registered Jan 2026
  • NCT07227311 · GlaxoSmithKline · Phase 2 · live · background · “Carfilzomib” · registered Nov 2025
  • NCT06892522 · AbbVie · Phase 2 · live · background · “Carfilzomib” · registered Mar 2025
Amgen61% of its industry studiesUS: ONYX PHARMS AMGEN (FDA 2012)EU: Amgen (EMA 2015)913 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Cyclophosphamide” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Cyclophosphamide” · registered Oct 2026
  • NCT07735637 · AstraZeneca · Phase 3 · live · background · “Cyclophosphamide” · registered Jul 2026
  • NCT07764978 · AstraZeneca · Phase 3 · live · background · “Cyclophosphamide” · registered Jul 2026
  • NCT07149857 · Johnson & Johnson · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2025
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed510 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Fludarabine” · registered Oct 2026
  • NCT07887672 · Gilead Sciences · Phase 3 · live · background · “Fludarabine” · registered Oct 2026
  • NCT07735637 · AstraZeneca · Phase 3 · live · background · “Fludarabine” · registered Jul 2026
  • NCT07764978 · AstraZeneca · Phase 3 · live · background · “Fludarabine” · registered Jul 2026
  • NCT06615479 · Bristol-Myers Squibb · Phase 3 · live · background · “Fludarabine” · registered Sep 2024
Beijing Biotech18% of its industry studies59 studies
elotuzumabRecent, repeated
Evidence
  • NCT07772024 · CellCentric Ltd. · Phase 3 · live · standard-care · “Investigator's choice of SAT” · registered Aug 2026
  • NCT07555938 · Hoffmann-La Roche · Phase 3 · live · comparator · “Elotuzumab” · registered Apr 2026
  • NCT06208150 · Johnson & Johnson · Phase 3 · live · comparator · “Elotuzumab” · registered Jan 2024
  • NCT06152575 · Pfizer · Phase 3 · live · comparator · “Elotuzumab” · registered Nov 2023
  • NCT05730036 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Elotuzumab” · registered Feb 2023
Bristol-Myers Squibb72% of its industry studiesUS: Bristol-Myers Squibb (FDA 2015)EU: Bristol-Myers Squibb (EMA 2016)55 studies
isatuximabRecent, repeated
Evidence
  • NCT07903506 · Gilead Sciences · Phase 3 · live · background · “Isatuximab” · registered Oct 2026
  • NCT07764978 · AstraZeneca · Phase 3 · live · background · “Isatuximab” · registered Jul 2026
  • NCT06119685 · Indapta Therapeutics, INC. · Phase 2 · live · background · “Isatuximab” · registered Oct 2023
  • NCT04126200 · GlaxoSmithKline · Phase 2 · live · background · “Isatuximab” · registered Oct 2019
  • NCT03989414 · Bristol-Myers Squibb · Phase 2 · live · background · “Isatuximab” · registered Jun 2019
Sanofi91% of its industry studiesUS: Sanofi (FDA 2020)EU: Sanofi (EMA 2020)33 studies
MelphalanRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07903506 · Gilead Sciences · Phase 3 · live · comparator · “Melphalan” · registered Oct 2026
  • NCT07735637 · AstraZeneca · Phase 3 · live · comparator · “Melphalan (part of ASCT)” · registered Jul 2026
  • NCT03412565 · Johnson & Johnson · Phase 2 · background · “Melphalan” · registered Jan 2018
  • NCT03217812 · Johnson & Johnson · Phase 3 · background · “Melphalan” · registered Jul 2017
  • NCT02195479 · Johnson & Johnson · Phase 3 · background · “Melphalan” · registered Jul 2014
Delcath Systems Inc.33% of its industry studies22 studies
Daratumumab and Hyaluronidase-fihjRecent, repeated
Evidence
  • NCT06952478 · celltrion · Phase 3 · live · comparator · “Darzalex Faspro(Daratumumab)” · registered Apr 2025
  • NCT06742138 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “DARZALEX FASPRO®” · registered Dec 2024
  • NCT04776018 · Takeda · Phase 2 · background · “Daratumumab and Hyaluronidase-fihj” · registered Feb 2021
Johnson & Johnson100% of its industry studies22 studies
selinexorRecent, repeated
Evidence
  • NCT07623798 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Selinexor Tablets” · registered May 2026
  • NCT07569757 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Selinexor tablets” · registered Apr 2026
Karyopharm Therapeutics Inc78% of its industry studiesUS: Karyopharm Therapeutics Inc (FDA 2019)EU: Menarini Group (EMA 2021)22 studies

32 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
mezigdomide☆ Track2 live phase-3 studies: NCT05519085, NCT05552976Bristol-Myers Squibb
daratumumabPhase 4 trial recorded☆ Track1 live phase-3 study: NCT06952478celltrion
HLX15☆ Track1 live phase-3 study: NCT06895512Fosun Pharma
elranatamabApproved: US 2023 · EU 2023☆ Track4 live phase-3 studies: NCT06152575, NCT05623020, NCT05020236Pfizer
CM336☆ Track2 live phase-3 studies: NCT07910903, NCT07181239Keymed Biosciences Co.Ltd

The 5 in phase 3 with the nearest primary completion, of 82 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (18)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.anitocabtagene autoleucel · Gilead Sciences · Phase 2 main aimNCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) — primary endpoint: Overall Response Rate (ORR) · 136 enrolled
  • 31 Dec 2026 est.GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003 · Innovent Biologics, Inc. · Phase 2 main aim+ Daratumumab vs Dexamethasone+ Daratumumab vs Lenalidomideadded to daratumumabNCT07764861 A Open-Label Phase in Participants With Multiple Myeloma — primary endpoint: MRD( Minimal Residue Disease) negativity rate at 24 weeks · 120 enrolled
  • 10 Jan 2027 est.mezigdomide · Bristol-Myers Squibb · Phase 3 main aimadded to Dexamethasoneadded to BortezomibNCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — primary endpoint: Progression-free Survival (PFS) · 810 enrolled

15 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Multiple Myeloma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 44 open · Proteasome inhibitors 24 open · Alkylating agents 19 open · Antibody-drug conjugates (ADCs) 16 open · Antimetabolites 6 open

Coming up

309studies finish main data collection within a year24 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger. 36 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 24 (4%) take healthy volunteers.

Recruiting studies that take each age, of 585
AgeWomenMen
1029 (5%)29 (5%)
18546 (93%)546 (93%)
30561 (96%)561 (96%)
40563 (96%)563 (96%)
50566 (97%)566 (97%)
65577 (99%)577 (99%)
75546 (93%)546 (93%)
85457 (78%)457 (78%)

Across all 3,763 studies, recruiting or not: 21% stop at 75 or younger and 6% at 65; 10% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple Myeloma studies take

Of 506 phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 150 mo33–75 · 413 studies43 mo27–71 · 212 studies57 mo39–99 · 201 studies
Phase 1/265 mo44–92 · 201 studies64 mo42–90 · 98 studies67 mo46–94 · 103 studies
Phase 257 mo35–95 · 506 studies38 mo27–77 · 93 studies59 mo40–96 · 413 studies
Phase 355 mo34–95 · 179 studies45 mo30–66 · 107 studies87 mo48–108 · 72 studies
Phase 442 mo30–57 · 28 studies——
Interventional, no phase38 mo20–79 · 186 studies—37 mo21–81 · 172 studies
Observational61 mo30–126 · 239 studies49 mo28–70 · 66 studies70 mo33–… · 173 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered21

Show 16 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,763. Browse all 3,763 → or search them.